## **CLAIMS**

1. A galactosamine derivative represented by the following formula (1):

$$R_{1}O$$
 $OR_{2}$ 
 $OR_{2}$ 
 $OR_{3}$ 
 $OR_{4}$ 
 $OR_{4}$ 
 $OR_{5}$ 
 $OR_{4}$ 
 $OR_{5}$ 
 $OR_{4}$ 
 $OR_{5}$ 
 $OR_{5}$ 
 $OR_{6}$ 
 $OR_{7}$ 
 $OR_{1}$ 
 $OR_{1}$ 
 $OR_{2}$ 
 $OR_{2}$ 
 $OR_{3}$ 
 $OR_{4}$ 
 $OR_{5}$ 

wherein  $R_1$ ,  $R_2$  and  $R_5$  each independently represents  $SO_3^-$  or H, and at least one of them represents  $SO_3^-$ ;

R<sub>3</sub> represents H, acetyl or SO<sub>3</sub>;

R<sub>4</sub> represents H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group;

X represents O, S, NH or  $CH_2$ ; and represents an  $\alpha$  bond or a  $\beta$  bond.

- 2. The galactosamine derivative according to claim 1, wherein  $R_1$  and  $R_2$  each is H;  $R_3$  is an acetyl group;  $R_4$  is a substituted or unsubstituted aryl group; and  $R_5$  is  $SO_3^-$ .
- 3. The galactosamine derivative according to claim 1, wherein R<sub>1</sub> is SO<sub>3</sub>; R<sub>2</sub> and R<sub>5</sub> each is H; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.

- 4. The galactosamine derivative according to claim 1, wherein R<sub>1</sub> and R<sub>5</sub> each is H; R<sub>2</sub> is SO<sub>3</sub><sup>-</sup>; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.
- 5. A sulfotransferase inhibitor which comprises the galactosamine derivative according to any one of claims 1 to 4.
- 6. The sulfotransferase inhibitor according to claim 5, which inhibits activity of a sulfotransferase having activity of transferring a sulfate group to a hydroxyl group bound to the 6-position carbon atom on the 4-sulfated galactosamine residue in the basic backbone of chondroitin sulfate.
- 7. A method for inhibiting activity of a sulfotransferase, which comprises allowing the galactosamine derivative according to any one of claims 1 to 4 to be present in an enzyme reaction system of the sulfotransferase.
- 8. Use of the galactosamine derivative according to any one of claims 1 to 4 as a sulfotransferase inhibitor.
- 9. Use of the galactosamine derivative according to any one of claims 1 to 4 for producing a sulfotransferase inhibitor.
- 10. A medicament based on inhibition of sulfotransferase activity, which comprises the galactosamine derivative according to any one of claims 1 to 4 as an active ingredient.

11. A medicament for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises the galactosamine derivative according to any one of claims 1 to 4 as an active ingredient.